Flexion Therapeutics
Biopharmaceutical company focused on advancing innovative, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis.
Launch date
Employees
Market cap
-
Enterprise valuation
$428m (Public information from Oct 2021)
Share price
$9.12 FLXN
Woburn Massachusetts (HQ)
Financials
Estimates*
| USD | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | 22.0m | 73.0m | 85.0m | 113m | 174m |
| % growth | - | - | - | 232 % | 16 % | 33 % | 54 % |
| EBITDA | - | (128m) | (157m) | (135m) | (91.0m) | (75.0m) | (31.0m) |
| % EBITDA margin | - | - | (714 %) | (185 %) | (107 %) | (66 %) | (18 %) |
| Profit | - | (137m) | (170m) | (150m) | (114m) | (102m) | (64.0m) |
| % profit margin | - | - | (773 %) | (205 %) | (134 %) | (90 %) | (37 %) |
| EV / revenue | - | - | 19.5x | 11.7x | 7.3x | - | - |
| EV / EBITDA | - | -7.3x | -2.7x | -6.3x | -6.9x | - | - |
| R&D budget | 42.9m | 47.3m | 50.6m | 68.2m | - | - | - |
| R&D % of revenue | - | - | 230 % | 93 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
$33.0m | Series A | ||
$9.0m | Series A | ||
$20.0m | Series B | ||
$65.0m | IPO | ||
$428m Valuation: $428m 5.0x EV/LTM Revenues -4.7x EV/LTM EBITDA | Acquisition | ||
| Total Funding | $62.0m | ||
